14 Most Undervalued NASDAQ Stocks to Buy Now

Page 9 of 14

6. Biogen Inc. (NASDAQ:BIIB)

Forward P/E Ratio as of September 20: 9.01

Number of Hedge Fund Holders: 55

Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics for an initial cash payment of $85 million and milestone payments.

The acquisition focuses on the ThecaFlex DRx, an implantable subcutaneous port and catheter device that is being researched for antisense oligonucleotide (ASO) intrathecal delivery. The system is intended to give patients with neurological illnesses a chronic medication delivery option that does not require repeated lumbar punctures.

Following the acquisition, Biogen Inc. (NASDAQ:BIIB) will be in charge of ThecaFlex DRx’s total development, production, and marketing. The PIERRE and PIERRE-PK clinical studies are now being used to assess the system in individuals with spinal muscular atrophy using SPINRAZA (nusinersen).

Biogen Inc. (NASDAQ:BIIB) is a multinational biopharmaceutical company dedicated to discovering, developing, and providing innovative treatments to patients with severe complex illnesses.

Page 9 of 14